Maravai LifeSciences

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 650

Market Cap: $2.2B

Website

Introduction: Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Clinical Trials

Nanoscope Therapeutics Hires Chief Technology, Manufacturing Officer

Ray Kaczmarek, a gene therapy manufacturing expert, joins Nanoscope Therapeutics as chief technology and manufacturing officer. Kaczmarek, with extensive experience in gene therapy manufacturing, will lead the commercial supply development for Nanoscope's gene therapies targeting inherited retinal diseases and geographic atrophy.

bioprocessintl.com

2 months ago

Repligen credits 10% revenue surge to new modalities and M&As

Repligen reported $155 million in Q3 revenue, a 10% YoY increase, driven by new modalities and CDMO equipment sales. The CEO highlighted the success of tailored solutions and strategic M&As, including Metenova and Tantti, positioning the company for growth in new modalities and protein business.

theglobeandmail.com

2 months ago

Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript

Maravai LifeSciences reported Q3 2024 earnings with $65M revenue, $13M adjusted EBITDA, and a $0.02 loss per share. Revenue was below expectations due to customer program shifts and market softness. The company highlighted innovation in mRNA synthesis and gene editing, and announced plans to acquire Officinae Bio's DNA and RNA businesses. Guidance for 2024 was lowered to $255M-$265M revenue, with adjusted EBITDA margin expected at 16%-18%. The acquisition is expected to close early 2025.

gurufocus.com

2 months ago

MRVI Stock Surges Amid Biotechnology Sector Fluctuations

Maravai Lifesciences Holdings, Inc. (MRVI) stock rose 5.09% to $7.84 with a trading volume of 531,902 shares. The company reported revenue of $73.40 million, a net loss of $7.59 million, and an EPS of -$0.06. 73% of analysts recommend buying MRVI, with no sell recommendations. The biotech industry declined 0.20%, but stocks like Neurogene Inc. and Tenaya Therapeutics, Inc. gained. Maravai specializes in nucleic acid production, biologics safety testing, and protein detection.

contractpharma.com

4 months ago

TriLink, Alphazyme Launch Novel RNA Polymerase For Safer mRNA Production

Maravai LifeSciences' subsidiaries, TriLink BioTechnologies and Alphazyme, introduce CleanScribe RNA Polymerase, an enzyme reducing dsRNA by up to 85% during mRNA IVT, enhancing safety and efficacy of mRNA-based therapeutics.

stocktitan.net

4 months ago

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

TriLink BioTechnologies and Alphazyme launch CleanScribe™ RNA Polymerase, reducing dsRNA in mRNA production by up to 85%, enhancing mRNA therapeutics safety and potency.

finance.yahoo.com

4 months ago

TriLink BioTechnologies & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

TriLink BioTechnologies and Alphazyme launch CleanScribe™ RNA Polymerase, reducing dsRNA in mRNA synthesis by up to 85% without compromising yield or integrity.

finance.yahoo.com

a year ago

15 Worst Performing Biotech Stocks in 2023

The biotech industry, valued at $1.2 trillion, faces challenges post-pandemic with reduced revenues, regulatory pressures, and decreased FDA approvals. Funding has significantly dropped, impacting innovation. In 2023, biotech stocks like Jazz Pharmaceuticals, Incyte Corporation, and Ultragenyx Pharmaceutical are among the worst performers, with significant YTD share price declines.

Home Terms & Conditions Privacy Policy